Last reviewed · How we verify
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
Details
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 116 |
| Start date | Wed Nov 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jul 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neuroendocrine Tumors
Interventions
- One injection of 68Ga-NOTA-AE105
- PET/CT
Countries
Denmark